Non-pharmacological therapies for patients with lymphangioleiomyomatosis: a systematic review and meta-analysis.
Yingwen Yu, Fang Lei, Huizi Wang
PMID 42312192WHAT IT FOUND
Structured exercise programmes helped people with LAM walk further in six minutes: 37.39 metres more on average across four small studies.
Lung function and quality of life did not improve significantly, and none of the studies was randomised.
Key findings
01Pooled across four studies, exercise-based programmes increased how far people with LAM could walk in six minutes by 37.39 metres (95% CI 27.79 to 46.98, p < 0.00001), and the studies agreed with each other (no heterogeneity).
02Neither of the other two pooled outcomes improved significantly: FEV₁ rose by 0.20 L (95% CI -0.02 to 0.42, p = 0.08) and quality of life changed by a mean difference of -0.19 (95% CI -0.56 to 0.18, p = 0.32).
03The whole review rests on five small studies and none of them was a randomised trial: three quasi-experimental studies, one retrospective analysis and one single-patient case report.
STILL TO COME
How it was doneWhat they foundWhat it means for PTs
Read the rest of this summary
You get three full summaries a month, free, and we do not ask for a card. Search, the TL;DRs and your library stay unlimited either way.
What it does not show
Five studies is very few, and every one of them was small, ranging from a single patient up to 58. There was no randomised trial at all, so the review cannot show that the exercise caused the improvement. Some of the pooled studies had no control group. Patients were compared with their own scores from before treatment, which means an improvement could come from practice with the walk test, day-to-day variation, or attention from staff rather than from the training. The authors state that the small samples give the review too little statistical power to detect small but real effects, which is one reason the confidence intervals around the pooled results are wide. Only exercise-based treatments were found. Despite the review setting out to cover surgical therapy, psychological counselling and nutritional support, no study reported results for any of them, so there is nothing here on those approaches. Follow-up ran from about 12 weeks to one year. In a chronic, progressive disease that may be too short to see whether benefits last. Quality of life was measured with different questionnaires in different studies, which the authors say makes the results hard to compare across studies. People with severe hypoxaemia (FEV₁ below 30%) were excluded from three of the studies, so the results do not tell you what happens in the most severely affected patients. One of the five included studies is a case report of one person, which the authors themselves excluded from the pooled analysis to avoid bias from single-case data.
Declared interests
The authors state that financial support was received for the work and/or its publication. The study was supported by an American Cancer Society Institutional Research Grant (#129819-IRG-21-049-61-IRG144), and that grant also paid the article processing charge. No individual author disclosures, and no statement that a company selling any of the treatments was involved, appear in the text supplied.
The easy way to misread this
Do not read the 37-metre improvement as proof that exercise changes the course of LAM. Some of the pooled studies had no control group and simply compared patients with their own scores from before treatment, and none of the five studies was randomised, so the gain in walking distance could come from something other than the training. The review also has nothing to say about surgery, psychological support or diet, because no study reported on them.
Summarised by AI from the full paper, without a clinician reviewing it. Check it against the source before it changes what you do. Read it on PubMed →